Stifel Nicolaus Raises Price Target for Zoetis to $195.00
November 2, 2023
🌥️Trending News
Stifel Nicolaus, a financial advisory and investment banking firm, recently raised the price target for Zoetis Inc ($NYSE:ZTS). to $195.00. Zoetis, a leading animal health company, develops, manufactures, and markets a broad range of animal health medicines and vaccines, as well as diagnostic products and genetic tests. They are a leader in developing innovative products and services that help veterinarians provide better care to livestock and pets. Zoetis offers products in the areas of livestock production, companion animal health, and aquaculture. Their products range from antibiotics, parasiticides, vaccines, therapeutic products, and diagnostics. The company has comprehensive disease prevention programs in place as well as a broad portfolio of products to improve animal welfare.
Additionally, they have invested in research and development to make animal healthcare more efficient and cost-effective. Stifel Nicolaus’s new price target of $195.00 is further indication of the company’s promising outlook. The firm’s strong recommendations are based on the continued success of the company’s product portfolio and its potential for long-term growth. Investors looking for a safe investment should consider Zoetis Inc., as it continues to provide solid returns in a volatile market.
Share Price
This has led to an overall increase in confidence in the stock, despite the recent dip in price. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Zoetis Inc. More…
| Total Revenues | Net Income | Net Margin |
| 8.22k | 2.21k | 27.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zoetis Inc. More…
| Operations | Investing | Financing |
| 2k | -858 | -2.04k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zoetis Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 13.75k | 9.13k | 10.04 |
Key Ratios Snapshot
Some of the financial key ratios for Zoetis Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 9.1% | 11.3% | 37.3% |
| FCF Margin | ROE | ROA |
| 15.6% | 42.0% | 13.9% |
Analysis
At GoodWhale, we have conducted an analysis of ZOETIS INC‘s fundamentals. Based on our Star Chart, we find that ZOETIS INC is strong in dividend, profitability, and medium in asset and growth. We classify ZOETIS INC as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Investors who are looking for long-term investments may be interested in ZOETIS INC, as the company has a high health score of 9/10 with regard to its cashflows and debt. This indicates that ZOETIS INC is capable to pay off debt and fund future operations. More…
Peers
Zoetis Inc. is a global animal health company that develops, manufactures, and markets a wide range of veterinary products. The company’s products include vaccines, parasiticides, pharmaceuticals, diagnostics, and biologics. Zoetis Inc. has a broad portfolio of products that are used in the prevention, treatment, and control of disease in animals. The company’s competitors include BioGaia AB, Krka d.d., and Phibro Animal Health Corp.
– BioGaia AB ($OTCPK:BIOGY)
Biogaia is a Swedish biotech company that markets probiotic products for infants, children, and adults. The company’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
Biogaia’s market cap is 800.05M as of 2022. The company has a Return on Equity of 10.86%. Biogaia’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
– Krka d.d. ($LTS:0HLK)
Krka d.d. is a Slovenian pharmaceutical company. It is the largest pharmaceutical company in Slovenia and one of the largest in the Balkans. The company was founded in 1959 and is headquartered in Novo mesto. Krka d.d. has a market cap of 2.77B as of 2022 and a Return on Equity of 12.85%. The company’s main products are prescription drugs, over-the-counter drugs, and medical devices.
– Phibro Animal Health Corp ($NASDAQ:PAHC)
Phibro Animal Health Corporation is a diversified animal health and specialty ingredients company with products in over 100 countries. The company’s products are sold through veterinarians, distributors, and feed stores. Phibro Animal Health Corporation’s mission is to improve the health and productivity of animals. The company’s products are used in a variety of animals, including cattle, swine, poultry, and aquaculture. Phibro Animal Health Corporation’s products are designed to improve the health and productivity of animals while providing a safe and healthy environment for them to live in.
Summary
Zoetis Inc is a major player in the animal health sector, and its stock has been a popular choice for investors. Recently, Stifel Nicolaus issued a new price target for the company of $195.00. On the same day, the stock price moved down slightly, indicating some investors may not be enthused with the new target.
Nevertheless, analysts remain bullish on the company due to its established presence in the market and strong portfolio of products and services. It is expected that the company will continue to grow in the near future, and its stock price should remain attractive for long-term investments.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
